The focus on disease-modifying therapies that affect the course of multiple sclerosis (MS) means that symptomatic therapies may be overlooked in the treatment of patients with MS.

Jonathan L. Carter, M.D., a neurologist at Mayo Clinic's campus in Phoenix/Scottsdale, Arizona, discusses symptomatic therapies and personalized treatment programs for patients with MS-related walking impairment, spasticity resulting from damage to the spinal cord due to MS lesions and MS-related fatigue.
 

Learn more about the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology — Developing new symptomatic therapies for MS.